News

Kerendia Approved for Heart Failure With Left Ventricular Ejection Fraction ≥40 Percent
Patients taking Kerendia saw significant reduction in cardiovascular death and hospitalization and urgent visits for heart ...
Pharmabiz3h
US FDA approves Bayer’s finerenone for new indication in patients with heart failure with left ventricular ejection fraction of ≥ 40%
US FDA approves Bayer’s finerenone for new indication in patients with heart failure with left ventricular ejection fraction of ≥ 40%: Berlin Wednesday, July 16, 2025, 13:00 H ...
Medical Dialogues3h
FDA Expands Finerenone Indication to Include Heart Failure
The FDA has broadened the approved use of finerenone (Kerendia) to include treatment for heart failure, according to an ...
AHA/ASA Journals17h
The Promise and Peril of Learning Algorithms and Predictive Models in Clinical Decision Support: Be Careful What You Train For
The era of predictive modeling enhanced with machine learning and artificial intelligence (AI) to aid clinical ...
FDA approves Kerendia for heart failure with ejection fraction of 40% or higher
Following priority review, the U.S. Food and Drug Administration approved Bayer's Kerendia (finerenone) for the treatment of ...
PMLive2h
Bayer’s Kerendia granted FDA approval for new heart failure indication
Bayer’s Kerendia (finerenone) has been approved by the US Food and Drug Administration (FDA) to treat heart failure (HF) patients with left ventricular ejection fraction (LVEF) of at least 40%.
PharmExec1d
FDA Approves Bayer’s Kerendia for Heart Failure with Preserved Ejection Fraction to Reduce Cardiovascular Death and Hospitalization Risk
Approval of Kerendia was based on results from the Phase III FINEARTS-HF trial, which demonstrated statistically significant ...
Daily Jang21h
FDA approves Kerendia for cardiac failure with LVEF ≥40 percent
In a significant move, the U.S. Food and Drug Administration granted approval for Kerendia for patients with heart failure ...
MedPage Today on MSN1d
Finerenone Gets Expanded FDA Approval in Heart Failure
The FDA expanded the indication for finerenone (Kerendia) in heart failure (HF), drug manufacturer Bayer announced.
TCTMD1d
FDA Approves Finerenone for HF Patients With Mildly Reduced or Preserved EF
The US Food and Drug Administration has approved the use of finerenone (Kerendia) in heart failure (HF) patients with mildly ...
Managed Healthcare Executive1d
FDA Expands Kerendia’s Use to Treat Common Form of Heart Failure
Kerendia was originally approved in July 2021 to reduce cardiovascular and kidney complications in patients with chronic ...
Zacks Investment Research on MSN1d
Bayer Gets FDA Nod for Label Expansion of Kerendia in Heart Failure
Bayer AG BAYRY announced that the FDA has approved a label expansion of kidney disease drug Kerendia (finerenone). The ...